J. Piercy

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
J. Piercy, James Piercy
Publication record
24 papers · 40 citations · H-index 4

PAPERS

64596 Assessing Physician and Patient-Reported Clinical and Humanistic Disease Burden Among White Patients with Atopic Dermatitis and those from Other Races/Ethnicities in the United States
20250 citationsauthor #8
Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles
20252 citationsauthor #9
Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study
20251 citationsauthor #10
Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis
20251 citationsauthor #8
64624 Comparing Advanced Treatment Utilization and Adherence, Disease Burden and Disconnect on Patient and Physician-Reported Severity Between White Patients with Atopic Dermatitis and Those Of Other Races/Ethnicities In the United States
20250 citationsauthor #8
An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
20251 citationsauthor #6
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
20250 citationsauthor #7
Impact of Choice of Tariff When Calculating Clinically Meaningful EQ‐5D Scores in Metabolic Dysfunction‐Associated Steatohepatitis
20250 citationsauthor #1
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States
20254 citationsauthor #4
Atopic Dermatitis Treatment with Topical Therapy Alone Results in Persistent Elevated Disease Severity and High Disease Control Dissatisfaction: Real-World Health Care Professional and Patient Perspectives
20240 citationsauthor #10
Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
20242 citationsauthor #2
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients
20240 citationsauthor #4
Correction: Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
20240 citationsauthor #2
53107 Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis
20240 citationsauthor #4
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location
20249 citationsauthor #3
Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan
20242 citationsauthor #7
Disease Course, Treatment Patterns and Goals Among Patients with Non-segmental Vitiligo Across Europe and the United States
20244 citationsauthor #4
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
20245 citationsauthor #4
Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients in Real World Practices (Prospect Study)
20240 citationsauthor #5
53788 The patient-reported impact of flares on quality of life in pediatric and adolescent patients with moderate-to-severe atopic dermatitis: a real-world study in the United States and Europe
20240 citationsauthor #8
42268 Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe
20230 citationsauthor #4
42928 The patient-reported impact of itch and sleep interference on pediatric and adolescent patients with moderate and severe atopic dermatitis: a real-world study in the United States and Europe
20230 citationsauthor #8
Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe
20239 citationsauthor #6
AB0907 Treatment patterns in psoriatic arthritis in us and europe: results from a real-world international survey
20180 citationsauthor #6

TIMELINE

2018 0 citations

2023 9 citations

2024 22 citations

2025 9 citations

COAUTHOR MAP

CONCEPT FOOTPRINT